Dhillon Robinder J S, Hasni Sarfaraz
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Room Number 3-2340, Bethesda, MD 20892, USA.
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Room Number 3-2340, Bethesda, MD 20892, USA.
Clin Geriatr Med. 2017 Feb;33(1):17-26. doi: 10.1016/j.cger.2016.08.002.
Sarcopenia represents a loss of muscle strength and mass in older individuals. Sarcopenia in the elderly has now become a major focus of research and public policy debate due to its impact on morbidity, mortality, and health care expenditure. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice. This is, in part, due to a lack of available diagnostic testing and uniform diagnostic criteria. The management of sarcopenia is primarily focused on physical therapy for muscle strengthening and gait training. There are no pharmacologic agents for the treatment of sarcopenia.
肌肉减少症表现为老年人肌肉力量和质量的丧失。由于其对发病率、死亡率和医疗保健支出的影响,老年人的肌肉减少症现已成为研究和公共政策辩论的主要焦点。尽管肌肉减少症具有临床重要性,但在常规临床实践中,它仍然未得到充分认识且管理不善。部分原因是缺乏可用的诊断测试和统一的诊断标准。肌肉减少症的管理主要侧重于通过物理治疗来增强肌肉和进行步态训练。目前尚无用于治疗肌肉减少症的药物。